|
18 Apr 2018 |
Merck Presents New Osteoarthritis Data at OARSI 2018 World Congress
|
|
17 Apr 2018 |
FDA approves Vonvendi [von Willebrand factor (recombinant)] for perioperative management of bleeding in adult patients with von Willebrand disease1
|
|
16 Apr 2018 |
Apitope announces positive results with novel treatment for Graves’ disease
|
|
15 Apr 2018 |
NGM Bio Announces Results From Phase 2 Study Of NGM282 In NASH Patients Demonstrating Clinically Significant Improvements In Liver Histology After 12 Weeks
|
|
12 Apr 2018 |
Nektar Announces Dosing of First Patient in Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 with CD122-Biased Agonist NKTR-214 in Patients with Advanced Solid Tumors
|
|
11 Apr 2018 |
Molecular Partners and AstraZeneca announce collaboration on Molecular Partners’ ongoing oncology clinical study with MP0250 in EGFR-mutated NSCLC
|
|
11 Apr 2018 |
Kineret® (anakinra) approved in the EU for the treatment of Still’s diseas
|
|
07 Apr 2018 |
Chiesi Group receives the European Marketing Authorisation for Lamzede (velmanase alfa)
|
|
05 Apr 2018 |
Stemline Therapeutics Announces Start of Rolling BLA Submission for SL-401
|
|
05 Apr 2018 |
Evolus Phase III European - Canadian Head-to-Head Trial of prabotulinumtoxinA Compared to Botox® Meets Primary Endpoint
|
|
03 Apr 2018 |
US FDA Approves BYDUREON for Use with Basal Insulin in Patients with Type 2 Diabetes with Inadequate Glycemic Control
|
|
03 Apr 2018 |
Palatin Technologies Presents Preclinical Oral Formulation Data on PL-8177, An Investigational Melanocortin Receptor 1 Agonist for Inflammatory Bowel Diseases
|
|
02 Apr 2018 |
Symic Bio Announces 12-Month Results from the SHIELD Trial of SB-030 in Peripheral Vascular Disease
|
|
02 Apr 2018 |
Radius Health Initiates Phase 3 Clinical Trial of Abaloparatide Injection for the Treatment of Male Osteoporosis
|
|
02 Apr 2018 |
Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA® (Pembrolizumab) Combination Trials
|
|
30 Mar 2018 |
Rights to botulinum toxin type b Neurobloc® in Europe transferred to Sloan Pharma, s.à.r.l.
|
|
29 Mar 2018 |
High Point Clinical Trials Center and Amyndas Pharmaceuticals Announce the Completion of the Complement C3 Inhibitor AMY-101 First in Human Study
|
|
28 Mar 2018 |
Mylan and Biocon Receive Approvals from the European Commission and TGA Australia for Semglee™, Biosimilar Insulin Glargine
|
|
28 Mar 2018 |
FDA approves inclusion of data on cardiovascular outcomes and severe hypoglycaemia in the Tresiba® label
|
|
26 Mar 2018 |
Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia
|
|
26 Mar 2018 |
Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial of PTG-100 for the Treatment of Ulcerative Colitis following Interim Analysis
|
|
26 Mar 2018 |
AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration for Bremelanotide for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women
|
|
24 Mar 2018 |
OPKO Health Enrolls First Patient in Phase 2b Study of OPK88003 to Treat Type 2 Diabetes
|
|
24 Mar 2018 |
CSL Behring Announces First Patient Enrollment in Phase 3 Clinical Trial of CSL112 to Assess Reduction of Early Recurrent Cardiovascular Events in Heart Attack Survivors
|
|
22 Mar 2018 |
BioArctic Receives Regulatory Approval in Norway for a Clinical Study in Patients With Complete Spinal Cord Injury
|
